Cart summary

You have no items in your shopping cart.

BC-DXI-843

SKU: orb1220098

Description

BC-DXI-843 is inhibitor of AIMP2-DX2, and is potential for development of novel therapeutics targeting AIMP2-DX2 in lung cancer.Optimization of hit BC-DXI-04 (IC50 = 40.1 μM) provided new potent sulfonamide based AIMP2-DX2 inhibitors. Among these, BC-DXI-843 showed improved inhibition against AIMP2-DX2 (IC50 = 0.92 μM) with more than 100-fold selectivity over AIMP2 in a luciferase assay. Several binding assays indicated that this compound effectively induces cancer cell apoptosis by specifically interrupting the interaction between DX2 and HSP70, which leads to the degradation of DX2 via Siah1-mediated ubiquitination.BC-DXI-843 demonstrated in vivo efficacy in a tumor xenograft mouse model (H460 cells) at a dosage of 50 mg/kg, suggesting it as a promising lead for development of novel therapeutics targeting AIMP2-DX2 in lung cancer.

Images & Validation

Key Properties

CAS Number2421117-98-6
MW546.66
Purity>98% (HPLC)
FormulaC28H26N4O4S2
SMILESCOC1=CC=C(C=C1)C1=CSC(NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NS(=O)(=O)C2=CC=C(C)C=C2)=N1
TargetAIMP2-DX2
SolubilityDMSO:245mg/ml (448.18 Mm; Need ultrasonic)

Bioactivity

In Vivo
BC-DXI-843 (50 mg/kg; intraperitoneally administered; every other day for 15 days) demonstrates In vivo efficacy in a tumor xenograft mouse model (H460 cells). Animal model: 7-week-old female BALB/cSLC-nu/nu mice bearing H460 cells xenograft. Dosage: 50 mg/kg. Administration: Intraperitoneally administered; every other day for 15 days. Result: The embedded tumor volume gradually declined after BC-DXI-843administration, but no changes in body weight were observed. The weight of the excised tumors after sacrifice had decreased in mice.
In Vitro
BC-DXI-843 (0.0316-31.6 μM; 72 hours) suppresses cancer cell proliferation in a DX2-dependent manner. The EC50 in A549 cells is 1.20 μM, which is similar to the IC50 for inhibition of DX2. However, no inhibition of WI-26 cells is observed, suggesting that BC-DXI-843 specifically reduces the viability of cancer cells. Cell Proliferation Assay Cell line: A549 cancer cells and WI-26 normal cells. Concentration: 0.0316, 0.1, 0.316, 1, 3.16, 10, 31.6 μM Incubation time: 72 hours. Result: The EC50 in A549 cells was 1.20 μM. No inhibition of WI-26 cells was observed.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Similar Products

  • BC-DXI-843 [orb1298911]

    >99.99% (May vary between batches)

    2421117-98-6

    546.66

    C28H26N4O4S2

    2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 1 ml x 10 mM (in DMSO)
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

BC-DXI-843 (orb1220098)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

200 mg
500 mg
2 mg
$ 110.00
5 mg
$ 150.00
10 mg
$ 230.00
25 mg
$ 400.00
50 mg
$ 580.00
100 mg
$ 840.00